

Press release
28 November, 2025

Curasight to present at HC Andersen Capital

Copenhagen, Denmark, 28 November 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kjær will present the Q3 2025 Interim report and the company's latest progress and strategy at HC Andersen Capital.

The presentations will include an update on the business progress made by the company during the first three quarters of 2025 and look ahead at the expected coming news flow.

Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain cancer, besides the newly reported green light for enrolling patients in the phase I trial with using uTREAT® in brain cancer, and its impact for the clinical development strategy for the coming year.

The HC Andersen Capital presentation will be webcasted live 14:00 - 14:30 (CET), Monday 1 December 2025 focusing on the brain cancer study.

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight's website, after the presentation is completed.

For more information – please [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.